Evidence map›Paper›PMID 39262344›Full record

ArticlePediatrics2024

Naloxone Dispensing to Youth Ages 10-19: 2017-2022.

Andrew Terranella, Gery Guy, Christina Mikosz

Abstract read
In one paragraph

Article in Pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Adolescent Substance Use Screening in the Emergency Department.Journal of the American College of Emergency Physicians open · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Naloxone Disparities in Adolescents: Access Laws Are Not Enough.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025
    Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Andrew TerranellaDivision of Overdose Prevention, Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia.
Gery GuyDivision of Overdose Prevention, Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia.
Christina MikoszDivision of Overdose Prevention, Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

BACKGROUND AND

objectivesNaloxone is lifesaving in the event of an opioid overdose but is underutilized in adolescents. Youth-serving clinicians can play a role in expanding naloxone access by offering it to all youth at risk for opioid-involved overdose, including by prescription. Understanding naloxone dispensing trends to youth can inform efforts to expand its use.

methodsWe used IQVIA National Prescription Audit Patient Insights data, which contains prescriptions dispensed from ∽48 900 retail pharmacies, representing 93% of all prescriptions from all payers in the United States. Cross-sectional analyses were used to describe naloxone dispensing trends among youth ages 10 to 19 years over time and by patient sex, out-of-pocket cost, prescriber specialty, and payer.

resultsFrom 2017 to 2022, 59 077 prescriptions for naloxone were dispensed to youth ages 10 to 19. Dispensing rates increased 669%, from 6.6 to 50.9 prescriptions per 100 000 adolescents, with increases each year. Dispensing varied by specialty and sex. Pediatricians accounted for an increasing proportion of prescriptions dispensed with a 6-year increase of 991%. Seventy-four percent of prescriptions were paid through commercial insurance. Although most prescriptions dispensed had low to 0 cost-sharing, 20% had out-of-pocket costs exceeding $25, and over 6% had out-of-pocket costs exceeding $75.

conclusionsPediatricians and other youth-serving clinicians can play an important role in expanding access to naloxone and harm reduction information by prescribing naloxone to all youth who are at risk for overdose. Clinician prescribing of naloxone can augment community distribution and over-the-counter access by making naloxone more widely available at all touchpoints with the health care system.

Indexed as

NaloxoneNarcotic AntagonistsAdolescentChildCross-Sectional StudiesDrug PrescriptionsFemaleHumansMalePractice Patterns, Physicians'United StatesYoung AdultNaloxoneNarcotic Antagonists

Identifiers

PMID39262344
PMCPMC11442117

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.